Jpmorgan Chase & CO Exact Sciences Corp Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Exact Sciences Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4,341,601 shares of EXAS stock, worth $309 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
4,341,601
Previous 12,384,516
64.94%
Holding current value
$309 Million
Previous $855 Million
78.55%
% of portfolio
0.02%
Previous 0.08%
Shares
13 transactions
Others Institutions Holding EXAS
# of Institutions
643Shares Held
166MCall Options Held
1.93MPut Options Held
1.23M-
Vanguard Group Inc Valley Forge, PA18.2MShares$1.29 Billion0.02% of portfolio
-
Capital World Investors Los Angeles, CA16.5MShares$1.17 Billion0.12% of portfolio
-
Wellington Management Group LLP Boston, MA14.8MShares$1.05 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$858 Million0.01% of portfolio
-
State Street Corp Boston, MA8.21MShares$584 Million0.02% of portfolio
About EXACT SCIENCES CORP
- Ticker EXAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 176,960,000
- Market Cap $12.6B
- Description
- Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...